Mark Enyedy
Directeur Général chez IMMUNOGEN, INC.
Fortune : 568 077 $ au 30/06/2024
Profil
Mark Joseph Enyedy is currently the President & Chief Executive Officer at ImmunoGen, Inc. He is also an Independent Director at BioMarin Pharmaceutical, Inc., a Director at Biotechnology Innovation Organization, a Director at American Cancer Society, New England Division, Inc., and an Independent Non-Executive Director at Ergomed Plc.
In the past, Mr. Enyedy served as the Chief Executive Officer & Director at Proteostasis Therapeutics, Inc. from 2011 to 2013.
He was also an Independent Director at Keryx Biopharmaceuticals, Inc. from 2017 to 2018, an Independent Director at Akebia Therapeutics, Inc. from 2018 to 2021, an Independent Director at Fate Therapeutics, Inc. from 2012 to 2018, and an Independent Director at LogicBio Therapeutics, Inc. from 2020 to 2022.
Additionally, he held the position of SVP, President-Transplant & Multiple Sclerosis at Genzyme Corp.
from 2011 to 2012 and served as the Executive VP & Head-Corporate Development at Shire Plc from 2014 to 2016.
He also worked as an Associate at Palmer & Dodge LLP.
Mr. Enyedy completed his undergraduate studies at Northeastern University and obtained a graduate degree from Harvard Law School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 21/05/2024 | 6 900 ( 0,00% ) | 568 077 $ | 30/06/2024 |
Postes actifs de Mark Enyedy
| Sociétés | Poste | Début |
|---|---|---|
| IMMUNOGEN, INC. | Directeur Général | 16/05/2016 |
| ERGOMED | Directeur/Membre du Conseil | 10/06/2021 |
| BIOMARIN PHARMACEUTICAL INC. | Directeur/Membre du Conseil | 27/12/2023 |
| American Cancer Society New England Division, Inc. | Directeur/Membre du Conseil | - |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Directeur/Membre du Conseil | - |
Anciens postes connus de Mark Enyedy
| Sociétés | Poste | Fin |
|---|---|---|
| LOGICBIO THERAPEUTICS, INC. | Directeur/Membre du Conseil | 16/11/2022 |
| AKEBIA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 02/06/2021 |
| KERYX BIOPHARMACEUTICALS | Directeur/Membre du Conseil | 12/12/2018 |
| FATE THERAPEUTICS, INC. | Directeur/Membre du Conseil | 02/05/2018 |
| ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Mark Enyedy
| Northeastern University | Undergraduate Degree |
| Harvard Law School | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| FATE THERAPEUTICS, INC. | Health Technology |
| AKEBIA THERAPEUTICS, INC. | Health Technology |
| ERGOMED | Commercial Services |
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| Entreprise privées | 9 |
|---|---|
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Proteostasis Therapeutics, Inc.
 Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA. | Health Technology |
| Palmer & Dodge LLP | Commercial Services |
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
| American Cancer Society New England Division, Inc. | |
LogicBio Therapeutics, Inc.
 LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
